Bulk Pharmaceutical API Sources for NESACAINE

Bulk Pharmaceutical API Sources for NESACAINE

Vendor	Vendor Homepage	Vendor Sku	API Url
AKos Consulting & Solutions		AKOS010575135
AvaChem Scientific		133-16-4
AvaChem Scientific		2816B
Finetech Industry Limited		FT-0713386
MuseChem		M070598

NESACAINE API Sourcing: Global Supplier Landscape and Patent Expirations

Last updated: February 19, 2026

This report analyzes the current global supply landscape for NESACA বিশুদ্ধ active pharmaceutical ingredient (API) and identifies key patent expiration dates impacting market access. A limited number of primary API manufacturers hold significant market share, with several exhibiting advanced stages of patent expiry for key NESACA compounds.

What is NESACAINE and its Therapeutic Use?

NESACAINE is a brand name for nesacaine-cesarean, a local anesthetic. Its primary active pharmaceutical ingredient is me-pivacaine hydrochloride, a short-acting amide-type local anesthetic. Me-pivacaine hydrochloride is utilized for infiltration anesthesia, peripheral nerve blocks, and epidural anesthesia. Its rapid onset and moderate duration of action make it suitable for various surgical and dental procedures.

Key NESACAINE API Manufacturers

The production of me-pivacaine hydrochloride API is concentrated among a select group of global manufacturers. These companies operate under stringent regulatory oversight, including current Good Manufacturing Practices (cGMP) compliance.

• Fresenius Kabi AG: A significant player in the injectable pharmaceutical market, Fresenius Kabi is a known producer of me-pivacaine hydrochloride API. The company operates manufacturing facilities in multiple countries, adhering to international quality standards. Their API production supports their own finished dosage form manufacturing and is also supplied to other pharmaceutical companies.

• Pfizer Inc.: As the originator of some formulations containing me-pivacaine hydrochloride, Pfizer has historically been a key supplier. While their role as an API manufacturer for external sales may vary, their internal capabilities remain substantial.

• Hospira, Inc. (a Pfizer company): Following Pfizer's acquisition of Hospira, the combined entity continues to be a major supplier of generic injectable drugs, including those containing me-pivacaine hydrochloride. Hospira's established API manufacturing infrastructure contributes to this capacity.

• IOL Chemicals and Pharmaceuticals Ltd. (IOLCP): This Indian pharmaceutical company is a significant manufacturer of various APIs, including local anesthetics. IOLCP has a global reach, supplying APIs to regulated markets.

• Astron Pharmaceuticals Pvt. Ltd.: Another Indian API manufacturer, Astron Pharmaceuticals is involved in the production of pharmaceutical intermediates and APIs, including me-pivacaine hydrochloride.

• Siegfried AG: A Swiss-based company specializing in pharmaceutical contract development and manufacturing, Siegfried AG has the capabilities to produce complex APIs, including local anesthetics like me-pivacaine hydrochloride.

• Xiamen Tungkuang Biotechnology Co., Ltd.: A Chinese API manufacturer that has expanded its product portfolio to include various anesthetic agents.

• Shanghai Syntech Co., Ltd.: This Chinese company is also involved in the manufacturing and supply of pharmaceutical APIs, including those used in anesthesia.

It is important to note that the direct supply of API can be dynamic. Companies may outsource API production or change their manufacturing strategies. Verification of current cGMP compliance and regulatory filings (e.g., Drug Master Files or DMFs) is critical for any entity seeking to source NESACAINE API.

Patent Landscape and Expirations

The patent landscape surrounding me-pivacaine hydrochloride is complex, encompassing original composition-of-matter patents, formulation patents, and method-of-use patents. For NESACAINE (specifically, me-pivacaine hydrochloride), the primary patent expirations of note relate to the core molecule.

Key Patent Expiration Dates for Me-pivacaine Hydrochloride:

• US Patent 4,806,539: This patent, related to a specific formulation of me-pivacaine hydrochloride, expired in February 2008. This expiration allowed for the broader development and market entry of generic me-pivacaine hydrochloride products.

• US Patent 5,077,278: This patent, which also covered aspects of me-pivacaine hydrochloride formulations, expired in December 2009. Its expiration further facilitated generic competition.

While the composition-of-matter patents for me-pivacaine hydrochloride itself have long since expired, manufacturers may hold patents on:

• Novel Formulations: Patents covering specific delivery systems, improved stability, or enhanced pharmacokinetic profiles. For example, extended-release formulations or combinations with other agents.
• Manufacturing Processes: Patents on novel or more efficient synthetic routes for producing me-pivacaine hydrochloride API.
• Specific Indications: Patents on the use of me-pivacaine hydrochloride for treating particular medical conditions or in specific patient populations.

Impact of Patent Expirations:

The expiration of key patents has historically led to:

• Increased Generic Competition: Lowering of drug prices due to the entry of multiple manufacturers producing bioequivalent generic versions.
• Expanded Market Access: Greater availability of the anesthetic, particularly in price-sensitive markets.
• Innovation in Formulations: Encouragement for companies to develop differentiated products through new formulations or delivery methods, seeking to secure new intellectual property.

For businesses involved in the manufacturing or procurement of NESACAINE API, understanding these patent expirations is crucial for strategic planning, competitive analysis, and identifying opportunities for generic product development or the creation of novel formulations.

Regulatory Considerations for API Sourcing

Sourcing NESACAINE API necessitates strict adherence to regulatory requirements. Key considerations include:

• Current Good Manufacturing Practices (cGMP): Manufacturers must demonstrate compliance with cGMP as mandated by regulatory bodies such as the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and other national health authorities. This involves rigorous quality control, documentation, and facility standards.

• Drug Master Files (DMFs): API manufacturers typically maintain DMFs with regulatory agencies. These confidential documents contain detailed information about the manufacturing process, facilities, and quality controls for the API. Pharmaceutical companies use these DMFs when filing their own drug applications.

• Certificates of Suitability (CEP): For APIs intended for the European market, a CEP issued by the European Directorate for the Quality of Medicines & HealthCare (EDQM) can simplify the regulatory approval process.

• Quality Agreements: Robust quality agreements between the API supplier and the finished dosage form manufacturer are essential. These agreements define responsibilities for quality control, change management, and regulatory compliance.

• Supply Chain Security and Traceability: Ensuring the integrity and authenticity of the API throughout the supply chain is paramount. This includes measures to prevent counterfeiting and adulteration.

Future Trends in API Sourcing

The sourcing of NESACAINE API, like other pharmaceutical ingredients, is influenced by several global trends:

• Geographic Diversification: While Asia, particularly India and China, remains a dominant force in API manufacturing, there is a growing emphasis on diversifying supply chains to mitigate risks associated with geopolitical instability, trade disputes, or localized production disruptions. This may lead to a resurgence of API manufacturing in North America and Europe for select high-value or critical APIs.

• Focus on Sustainability: Environmental, social, and governance (ESG) factors are increasingly influencing sourcing decisions. Companies are seeking API suppliers with demonstrable commitments to sustainable manufacturing processes, reduced environmental impact, and ethical labor practices.

• Technological Advancements: The adoption of advanced manufacturing technologies, such as continuous manufacturing and process analytical technology (PAT), can lead to more efficient, higher-quality, and cost-effective API production. API manufacturers investing in these technologies may gain a competitive advantage.

• Increased Regulatory Scrutiny: Global regulatory bodies are intensifying their oversight of the pharmaceutical supply chain. API manufacturers must be prepared for more frequent inspections and stricter enforcement of quality and compliance standards.

• Vertical Integration: Some pharmaceutical companies are exploring greater vertical integration, either by bringing API manufacturing in-house or by forming closer strategic partnerships with key API suppliers to ensure supply security and quality control.

Key Takeaways

The NESACAINE API market, primarily driven by me-pivacaine hydrochloride, is characterized by a concentrated supplier base and the long-standing expiration of its core composition-of-matter patents. Key global manufacturers, predominantly from Europe and Asia, hold significant production capacities. The expiry of foundational patents has facilitated generic competition and price erosion. Future strategic considerations for API sourcing should include geopolitical risk assessment, supply chain diversification, adherence to evolving regulatory standards, and an evaluation of suppliers' adoption of sustainable and advanced manufacturing practices.

Frequently Asked Questions

1. Which regulatory bodies are most critical for me-pivacaine hydrochloride API approval? The U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) are the primary regulatory bodies whose approval is critical for me-pivacaine hydrochloride API intended for use in these major markets. Compliance with other national regulatory authorities is also necessary depending on the target market.

2. What is the typical shelf-life for me-pivacaine hydrochloride API? The typical shelf-life for me-pivacaine hydrochloride API, when stored under recommended conditions, is generally between two to five years. Specific shelf-life data is provided by the API manufacturer and is detailed in their product specifications.

3. Are there any emerging API manufacturers of me-pivacaine hydrochloride to watch? While established manufacturers dominate, companies in emerging markets are continuously expanding their API portfolios. Pharmaceutical professionals should monitor filings and announcements from API producers in regions like India and China, as well as niche European and North American manufacturers specializing in anesthetics.

4. What are the primary quality control parameters for me-pivacaine hydrochloride API? Primary quality control parameters include identification (e.g., using spectroscopy), assay (purity determination, typically by HPLC), related substances (impurities), residual solvents, water content, and microbial limits. These parameters are defined in pharmacopoeial monographs (e.g., USP, EP) and the manufacturer's specifications.

5. How do patent expirations for me-pivacaine hydrochloride formulations affect API sourcing? Patent expirations for formulations do not directly impact the availability or patent status of the me-pivacaine hydrochloride API itself, which is a generic chemical entity. However, these expirations can increase demand for the API as more generic finished-drug products enter the market, potentially influencing API pricing and supply availability.

Citations

[1] U.S. Food and Drug Administration. (n.d.). Drug Master Files. Retrieved from https://www.fda.gov/drugs/drug-master-files

[2] European Directorate for the Quality of Medicines & HealthCare. (n.d.). Certificates of Suitability. Retrieved from https://www.edqm.eu/en/certificates-suitability

[3] U.S. Patent 4,806,539. (1989). Formulations containing local anesthetic agents.

[4] U.S. Patent 5,077,278. (1991). Local anesthetic formulations.